Protalix BioTherapeutics Inc (PLX)
1.17
-0.04
(-3.31%)
USD |
NYAM |
Apr 25, 10:18
Protalix BioTherapeutics Cash from Operations (Quarterly): 3.595M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.595M |
| September 30, 2023 | -6.888M |
| June 30, 2023 | 4.973M |
| March 31, 2023 | -2.998M |
| December 31, 2022 | -2.611M |
| September 30, 2022 | -9.204M |
| June 30, 2022 | -7.356M |
| March 31, 2022 | -5.829M |
| December 31, 2021 | -5.087M |
| September 30, 2021 | -1.88M |
| June 30, 2021 | 6.516M |
| March 31, 2021 | -9.834M |
| December 31, 2020 | -7.55M |
| September 30, 2020 | -3.604M |
| June 30, 2020 | -7.835M |
| March 31, 2020 | -7.117M |
| December 31, 2019 | -3.687M |
| September 30, 2019 | -3.225M |
| June 30, 2019 | -5.17M |
| March 31, 2019 | -7.276M |
| December 31, 2018 | -4.004M |
| September 30, 2018 | 13.64M |
| June 30, 2018 | -7.964M |
| March 31, 2018 | -9.413M |
| December 31, 2017 | 17.59M |
| Date | Value |
|---|---|
| September 30, 2017 | -10.54M |
| June 30, 2017 | -8.619M |
| March 31, 2017 | -8.426M |
| December 31, 2016 | -7.338M |
| September 30, 2016 | -3.443M |
| June 30, 2016 | -11.69M |
| March 31, 2016 | -9.625M |
| December 31, 2015 | -3.857M |
| September 30, 2015 | -8.66M |
| June 30, 2015 | -5.346M |
| March 31, 2015 | -6.421M |
| December 31, 2014 | -4.874M |
| September 30, 2014 | -9.548M |
| June 30, 2014 | -6.519M |
| March 31, 2014 | -8.34M |
| December 31, 2013 | -4.742M |
| September 30, 2013 | -8.216M |
| June 30, 2013 | -8.109M |
| March 31, 2013 | -9.586M |
| December 31, 2012 | 1.821M |
| September 30, 2012 | -8.029M |
| June 30, 2012 | 13.12M |
| March 31, 2012 | -6.281M |
| December 31, 2011 | -6.612M |
| September 30, 2011 | -8.147M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-9.834M
Minimum
Mar 2021
6.516M
Maximum
Jun 2021
-3.936M
Average
-5.087M
Median
Dec 2021
Cash from Operations (Quarterly) Benchmarks
| Agenus Inc | -40.40M |
| InfuSystems Holdings Inc | 4.658M |
| Corbus Pharmaceuticals Holdings Inc | -6.009M |
| AIM ImmunoTech Inc | -9.758M |
| Armata Pharmaceuticals Inc | -8.106M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.342M |
| Free Cash Flow | -2.467M |
| Free Cash Flow Per Share (Quarterly) | 0.0386 |
| Free Cash Flow to Equity (Quarterly) | 3.286M |
| Free Cash Flow to Firm (Quarterly) | 4.108M |
| Free Cash Flow Yield | -2.71% |